FDA to beef up warnings on use of long-acting opioid pain drugs
Sept 10 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it would require new language on the labels of long-acting and extended-release opioids, restricting their use and underscoring dangers of abuse, death and damage to newborns of mothers taking the widely used pain medicines.
The FDA also said it would require additional studies of such medicines to assess known risks of abuse, overdose and death.
- White House reverses, says Obama met uncle and lived with him during law school
- With song and sadness, South Africans mourn Mandela |
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- UPDATE 1-Study casts doubt on whether extra vitamin D prevents disease